Morocco Pharmaceutical Market 2024-2030

    In Stock




    • The Moroccan pharmaceutical industry satisfies 65% of the internal demand for medicines, while 35% continues to be imported.
    • 60 wholesale distributors guarantee 80% of the supply for the 11,000 existing pharmacies.
    • The procurement of pharmaceutical products can represent up to 50% of health expenditure in developing countries, fraud and corruption can result in the disappearance of almost 25% of medicines purchased (WHO, 2009). 
    • The role of the Moroccan Pharmaceutical Industry Association (AMIP) as a professional association, also seems crucial for the establishment of a culture of integrity in this important sector. 
    • The Moroccan pharmaceutical industry constitutes the second largest chemical industry in Morocco, and ranks second in the African continent.
    • The growth is driven by factors such as increasing population, rising healthcare awareness, and government initiatives promoting access to healthcare.
    • The Moroccan government is implementing various initiatives to improve access to healthcare and promote the pharmaceutical industry.
    • The government also planned actions to reduce retail mark-ups and VAT for chronic illness medicines, and to improve the medicine supply chains, increase the number of qualified staff and facilities and promote the rational prescription of medicines.
    • Growth in Morocco is projected to slow to 1.1% in 2022, as agricultural output declines by 17.3% due to an unprecedented drought.
    • Increased investment in R&D would allow Morocco to develop its own innovative drugs and technologies.
    • The Moroccan pharmaceutical industry is considered a leading platform in Africa
    • The Moroccan government seeks partnerships with private companies to develop the pharmaceutical industry.



    The Moroccan population is becoming increasingly aware of the importance of healthcare. This is leading to increased demand for pharmaceuticals.


    Patented medicines represented 41.2% of the total market and 58.1% of the prescription one, but this part would decrease in the coming years due to encouragement of generics and (very recently) biosimilars, because their prescription is strongly supported by the Moroccan government.


    The Moroccan government is revising its regulatory framework to align with international standards. This creates a more transparent and predictable environment for pharmaceutical companies.


    Technologies like e-commerce, online pharmacies, and telemedicine are gaining traction in Morocco. This presents opportunities for companies to develop innovative distribution channels and reach a wider customer base.


    According to Business Monitor International (BMI) study, currently generics and biosimilars cover 80-90% of the public medicines market and only 25% of the private one. The OTC sector would undergo the same competition from generics, and is expected to decrease its share up to 22.8% in 2026.


    Currently pharmaceutical sales represent approx. 1,47% of Morocco’s GDP and 24.4% of the total health expenditure of the African countries.


    According to AMIP, the local pharmaceutical production covers 65% of the internal pharmaceutical market, while 10% is intended for export. A great part of active pharmaceutical ingredients are imported from abroad, says BMI.



    The pharmaceutical manufacturing industry is growing in Morocco. Numerous regional pharmaceutical firms manufacture a vast array of goods, such as generic medications, medical equipment, and vaccines.


    There are three professional associations in the country representing the different industries, i.e. the Moroccan Association of Pharmaceutical Industry (AMIP), Les enterprises du medicament au Maroc (LEMM) of multi-national companies and the Moroccan Association of Generic Medicines (AMMG).


    As reported by the Association of the Pharmaceutical Industry, the Moroccan National Laboratory for the Control of Medicines (LNCM) has been certified both by the World Health Organization and the European Directorate for the Quality of Medicines, thus acknowledging the quality of the production run under GMP conditions. 


    The majority of generic medicines present on the Moroccan market are locally produced, while Africa and the Middle East are the preferred areas of export (counting for 8% of the generics’ production).


    Regulatory procedures are under the control of the Drugs and Pharmaceutical Directorate of the Ministry of Health. The latter is divided into three sub directions: firstly, the Division of Pharmacy, secondly, the Pharmaceutical sector monitoring department and finally, the LNCM which is responsible for the quality review of pharmaceutical documentations as well as of lab-testings.


    The nation’s reliance on pharmaceutical imports has decreased as a result of this indigenous production. 

    Although Morocco has increased its ability to produce pharmaceuticals, it still imports some of these goods, particularly specialized medications and raw ingredients. These imports aid in meeting the need for a wide range of healthcare products. 


    With a network of pharmacies and medical facilities serving the populace, Morocco has a well-organized system for distributing pharmaceutical items. A wide range of people have access to medications due to the public and private pharmaceutical distribution systems.



    infographic: Morocco Pharmaceutical Market, Morocco Pharmaceutical Market Size, Morocco Pharmaceutical Market Trends, Morocco Pharmaceutical Market Forecast, Morocco Pharmaceutical Market Risks, Morocco Pharmaceutical Market Report, Morocco Pharmaceutical Market Share


    The Morocco pharmaceutical market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.



    • Morocco’s Ministry of Economy and Finance announced the approval of a two-year USD 5 billion Flexible Credit Line (FCL) by the IMF Executive Board. This financial support is expected to bolster the country’s economic resilience and potentially impact the pharmaceutical industry by promoting stability and facilitating investments.
    • Sanofi Morocco inaugurated a new production line for insulin cartridges at its plant in Casablanca. This expansion aims to address the growing demand for insulin in Morocco and neighboring countries.
    • The Moroccan Agency for Development and Investment (AMDI) signed a partnership agreement with the Moroccan Association of Pharmaceutical Industries (AMIP) to support the development of the local pharmaceutical industry. The collaboration focuses on attracting investments, promoting R&D, and facilitating exports.
    • The World Health Organization (WHO) awarded Morocco the status of “Maturity Level 4” in its pharmaceutical regulatory system assessment. This recognition acknowledges the country’s significant progress in ensuring the quality, safety, and efficacy of pharmaceuticals.
    • The Moroccan pharmaceutical company So Thema launched a new production line for sterile injectable drugs, further expanding its manufacturing capabilities and product portfolio.



    Boron Morocco: Introduced “Oscillo coccineum 1000 doses,” a high-dose homeopathic medication for influenza-like symptoms. Oscillo coccineum reduces the duration and severity of flu symptoms such as body aches, headache, fever, chills, and fatigue.


    Mead Pharma Morocco: Launched “Voltaire Emulex,” a topical pain relief gel. Voltaire Emulex Extra Strength contains the non-steroidal anti-inflammatory drug (NSAID), diclofenac dimethylamine. Diclofenac dimethylamine works to relieve pain and reduce inflammation (swelling).


    Sanofi Morocco: Launched “Toujeo Solostar,” a long-acting insulin analog for diabetes management. Toujeo Solostar is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.


    GlaxoSmithKline (GSK) Morocco: Introduced “Seretide Discus,” a combination inhaler for asthma and COPD treatment. It is a fixed dose combination of salmeterol and fluticasone propionate for use in patients with asthma and chronic.




    Morocco Pharmaceutical Market By Product Type

    • Prescription drugs
    • Over-the-counter (OTC) drugs
    • Generics
    • Biologics
    • Vaccines


    Morocco Pharmaceutical Market By Therapy Area

    • Cardiovascular diseases
    • Pain
    • Diabetes
    • Cancer
    • Respiratory diseases


    Morocco Pharmaceutical Market By Distribution Channel

    • Public sector
    • Pharmacies
    • Hospitals
    • Public health facilities
    • Online pharmacies


    Morocco Pharmaceutical Market By Geography

    • Urban areas
    • Rural areas



    • Sanofi Maroc
    • Cooper Pharma
    • Sothema
    • Laprophan
    • Pharmasynthese
    • Boiron Morocco
    • Meda Pharma Morocco
    • GSK (GlaxoSmithKline) Morocco
    • AstraZeneca Morocco
    • Merck Maroc



    1. What is the current size of the Moroccan pharmaceutical market?
    2. What is the projected market size for 2023 and 2030?
    3. What is the expected CAGR for the market over the next five years?
    4. What are the main segments of the Moroccan pharmaceutical market?
    5. What is the market share of each segment?
    6. Which segments are growing fastest and why?
    7. What are the key drivers of growth in the Moroccan pharmaceutical market?
    8. How are demographic trends, healthcare awareness, and government policies influencing the market?
    9. What are the challenges and opportunities in the Moroccan pharmaceutical market?
    10. Who are the major players in the Moroccan pharmaceutical market?
    11. What are their market shares and product portfolios?
    12. How are these players competing in the market?
    13. What are the regulatory requirements for pharmaceuticals in Morocco?
    14. How are these regulations impacting the market?
    15. What are the future prospects for regulatory changes?
    16. What is the current state of R&D in the Moroccan pharmaceutical industry?
    17. How much are companies investing in R&D?
    18. What are the key areas of focus for R&D?
    19. How much of the Moroccan pharmaceutical market is dependent on imports?
    20. What are the main export markets for Moroccan pharmaceuticals?
    21. What are the key trends emerging in the Moroccan pharmaceutical market?
    22. How are these trends impacting the market?


    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Research Methodology
    4 Executive Summary
    5 Average B2B Price
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Challenges in Moroccan Pharmaceutical Market
    14 Impact of Government Policies in Moroccan Pharmaceutical Market
    15 Research and Development in Moroccan Pharmaceutical Market
    16 New product development in past 12 months
    17 Market Size, Dynamics and Forecast by Therapy Area, 2024-2030
    18 Market Size, Dynamics and Forecast by Drug Type, 2024-2030
    19 Market Size, Dynamics and Forecast by Molecule type, 2024-2030
    20 Market Size, Dynamics and Forecast by Distribution Channel, 2024-2030
    21 Gross margin and average profitability of suppliers
    22 Competitive Landscape
    23 M&A in past 12 months
    24 Growth strategy of leading players
    25 Market share of vendors, 2023
    26 Company Profiles
    27 Unmet needs and opportunity for new suppliers
    28 Conclusion
      Your Cart
      Your cart is emptyReturn to Shop